The COHEM 2014 Congress will focus on the following topics:
 |
Non-Malignant Hematology |
|
CML |
|
 |
When generic imatinib becomes more available, should initial therapy be with imatinib or second generation tyrosine-kinase inhibitors? |
 |
Should therapy be changed in patients with CML in chronic phase and "suboptimal” response after 6 months? |
|
|
CLL |
|
 |
Is minimal residual disease a therapy end-point? |
 |
Are imaging techniques needed in the routine evaluation of newly diagnosed patients with CLL? |
|
|
Acute Leukemia / MDS |
|
Myleofibrosis |
|
 |
Patients responding to Ruxolitinib should not be considered for allogeneic transplantation? |
|
|
Lymphoma |
|
 |
Should therapy be changed in patients with DLBCL if PET scan remain positive after 2 (or 4) courses of treatment? |
 |
Should autologous transplantation be offered to all patients with Peripheral T Cell Lymphoma after induction therapy? |
|
|
Hodgkin’s lymphoma |
|
 |
Should Brentuxumabbe moved to upfront therapy? |
|
|
Myeloma |
|
 |
Patients with "high risk” myeloma who do not benefit from autologous transplant should be considered for allogeneic transplant? |
 |
Should bisphosphonates be continued indefinitely after chemotherapy is initiated? |
|
|